Trials / Completed
CompletedNCT04990427
CLBS201 in Patients with Chronic Kidney Disease (CKD) and Type 2 Diabetes Mellitus (T2DM)
A Phase 1 Open-Label, Proof-of-Concept Study to Evaluate the Safety and Efficacy of CLBS201 Autologous Peripheral Blood-Derived CD34+ Cells in Subjects with Chronic Kidney Disease and Type 2 Diabetes Mellitus
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 6 (actual)
- Sponsor
- Lisata Therapeutics, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
CLBS201 will evaluate the safety, tolerability, and therapeutic effect in subjects with CKD and T2DM.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | CLBS201 | 1 x 10\^6 to 300 x 10\^6 autologous CD34+ cells |
Timeline
- Start date
- 2022-01-10
- Primary completion
- 2023-01-26
- Completion
- 2023-01-26
- First posted
- 2021-08-04
- Last updated
- 2024-10-09
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04990427. Inclusion in this directory is not an endorsement.